Evaluating Diagnostic Accuracy and Inter-reader Agreement of the Prostate Imaging After Focal Ablation Scoring System.

Authors:
Gelikman DG; Kenigsberg AP; Mee Law Y; Yilmaz EC; Harmon SA and 12 more

Journal:
Eur Urol Open Sci

Publication Year: 2024

DOI:
10.1016/j.euros.2024.02.012

PMCID:
PMC10925932

PMID:
38468864

Journal Information

Journal Title: Eur Urol Open Sci

Detailed journal information not available.

Publication Details

Subject Category: Urology & Nephrology

Available in Europe PMC: Yes

Available in PMC: Yes

PDF Available: No

Transparency Score
4/6
66.7% Transparent
Transparency Indicators
Click on green indicators to view evidence text
Core Indicators
Evidence found in paper:

"appendix a supplementary data the following are the supplementary data to this article: supplementary data 1 appendix a supplementary data to this article can be found online at https://doi org/10 1016/j euros2024 02 012 ."

Code Sharing
Evidence found in paper:

"

 Financial disclosures: Baris Turkbey certifies that all conflicts of interest, including specific financial interests and relationships and affiliations relevant to the subject matter or materials discussed in the manuscript (eg, employment/affiliation, grants or funding, consultancies, honoraria, stock ownership or options, expert testimony, royalties, or patents filed, received, or pending), are the following: Bradford J. Wood: principal investigator on Cooperative Research and Development Agreement (CRADA) between National Institutes of Health (NIH) and Philips and CRADAs with industry partners unrelated to this work; travel support related to CRADAs; royalties from NIH related to Philips licensing agreement; and patents planned, issued, or pending. Peter L. Choyke: receives payment from royalties paid to the US government for patents on MRI US fusion biopsy licensed to Philips Medical. Peter A. Pinto: institutional CRADA with Philips; royalties from NIH related to Philips licensing agreement; and NIH-related patents planned, issued, or pending (U.S. patent nos. 8 447 384 and 10 215 830). Baris Turkbey: CRADAs with NVIDIA and Philips; royalties from NIH; and patents planned, issued, or pending in the field of artificial intelligence. Financial disclosures:"

Evidence found in paper:

"

Financial disclosures: Baris Turkbey certifies that all conflicts of interest, including specific financial interests and relationships and affiliations relevant to the subject matter or materials discussed in the manuscript (eg, employment/affiliation, grants or funding, consultancies, honoraria, stock ownership or options, expert testimony, royalties, or patents filed, received, or pending), are the following: Bradford J. Wood: principal investigator on Cooperative Research and Development Agreement (CRADA) between National Institutes of Health (NIH) and Philips and CRADAs with industry partners unrelated to this work; travel support related to CRADAs; royalties from NIH related to Philips licensing agreement; and patents planned, issued, or pending. Peter L. Choyke: receives payment from royalties paid to the US government for patents on MRI US fusion biopsy licensed to Philips Medical. Peter A. Pinto: institutional CRADA with Philips; royalties from NIH related to Philips licensing agreement; and NIH-related patents planned, issued, or pending (U.S. patent nos. 8 447 384 and 10 215 830). Baris Turkbey: CRADAs with NVIDIA and Philips; royalties from NIH; and patents planned, issued, or pending in the field of artificial intelligence. 

Funding/Support and role of the sponsor: This research was made possible through the NIH Medical Research Scholars Program, a public-private partnership supported jointly by the NIH and generous contributions to the Foundation for the NIH from the American Association for Dental Research, the Colgate-Palmolive Company, and other private donors. This research was additionally supported by the Intramural Research Program of the National Cancer Institute, National Institutes of Health."

Protocol Registration
Open Access
Paper is freely available to read
Additional Indicators
Replication
Novelty Statement
Assessment Info

Tool: rtransparent

OST Version: N/A

Last Updated: Aug 05, 2025